Avandia Market Share Stabilizing, GSK CEO Garnier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In his last earnings presentation, Garnier says it is unclear whether the type 2 diabetes drug will become a growth driver again.
You may also be interested in...
AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis
HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval
Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval
Symbicort's rapid onset of action and lack of pneumonia signal could be competitive advantages as the drug enters the market with its newly approved use for chonic obstructive pulmonary disease